DexCom (NASDAQ:DXCM) Price Target Raised to $86.00 at Sanford C. Bernstein

DexCom (NASDAQ:DXCM - Get Free Report) had its price objective increased by stock analysts at Sanford C. Bernstein from $82.00 to $86.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an "outperform" rating on the medical device company's stock. Sanford C. Bernstein's target price points to a potential upside of 17.10% from the stock's current price.

Several other equities research analysts have also issued reports on DXCM. Piper Sandler reiterated an "overweight" rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday. Morgan Stanley decreased their price target on DexCom from $120.00 to $75.00 and set an "equal weight" rating for the company in a research note on Friday, July 26th. Robert W. Baird upped their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, August 5th. Finally, UBS Group cut their price target on shares of DexCom from $163.00 to $95.00 and set a "buy" rating for the company in a research note on Friday, July 26th. Six analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Trading Down 1.9 %

NASDAQ:DXCM traded down $1.41 on Friday, reaching $73.44. The company's stock had a trading volume of 14,560,038 shares, compared to its average volume of 3,904,948. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The business's 50-day moving average price is $70.11 and its two-hundred day moving average price is $98.24. The firm has a market cap of $29.21 billion, a PE ratio of 47.38, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. The business had revenue of $994.20 million for the quarter, compared to analysts' expectations of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. Equities research analysts anticipate that DexCom will post 1.69 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 426 shares of the business's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the firm's stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Team Hewins LLC increased its stake in shares of DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company's stock valued at $354,000 after buying an additional 83 shares during the period. Bleakley Financial Group LLC raised its holdings in DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company's stock worth $951,000 after purchasing an additional 87 shares during the last quarter. Capital Insight Partners LLC lifted its position in shares of DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company's stock worth $418,000 after purchasing an additional 90 shares during the period. HM Payson & Co. boosted its stake in shares of DexCom by 6.0% in the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company's stock valued at $247,000 after purchasing an additional 100 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of DexCom by 0.3% during the first quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company's stock worth $5,801,000 after buying an additional 105 shares during the period. Institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.